Cerus Corporation (CERS) vs Puma Biotechnology, Inc. (PBYI)
A side-by-side comparison of Cerus Corporation and Puma Biotechnology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CERS
Cerus Corporation
$2.34HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PBYI
Puma Biotechnology, Inc.
$9.50HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CERS vs PBYI
growth of $100 · dividends reinvested · last 10yCERS -62.6% (-9.4%/yr)PBYI -85.3% (-17.4%/yr)CERS compounded faster over this window
CERS PBYI
CERS vs PBYI: by the numbers
- •PBYI is the larger company ($484M vs $472M market cap).
- •PBYI is profitable (11.55% net margin) while CERS runs a net loss (-3.06%).
- •CERS grew revenue faster over the past five years (15.74% vs 0.29% CAGR).
Metrics side by side
Valuation
| Metric | CERS | PBYI |
|---|---|---|
| P/E ratio | N/A | 18.40 |
| Forward P/E | N/A | 25.00 |
| P/S ratio | 2.13 | 2.09 |
| P/B ratio | 6.73 | 3.49 |
| EV / EBITDA | 8036.17 | 10.41 |
| FCF yield | N/A | 8.50% |
Profitability
| Metric | CERS | PBYI |
|---|---|---|
| Gross margin | 52.05% | 74.83% |
| Operating margin | -0.73% | 13.16% |
| Net margin | -3.06% | 11.55% |
| ROE | -9.69% | 19.28% |
| ROIC | -1.08% | 18.26% |
Growth (annualized)
| Metric | CERS | PBYI |
|---|---|---|
| Revenue CAGR (5Y) | 15.74% | 0.29% |
| FCF CAGR (5Y) | N/A | 90.51% |
| Total return CAGR (5Y) | -17.30% | 9.26% |
Frequently asked
- Which has grown faster, CERS or PBYI?
- Over the past five years, CERS grew revenue faster — CERS at a 15.74% CAGR versus PBYI at 0.29%.
- Is CERS or PBYI more profitable?
- PBYI runs the higher net margin — CERS at -3.06% versus PBYI at 11.55%.
- How have CERS and PBYI total returns compared?
- Over the past 10 years, CERS delivered -9.37% and PBYI delivered -17.43% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Puma Biotechnology P/E ratioCerus ROEPuma Biotechnology ROECerus operating marginPuma Biotechnology operating marginCerus revenue growthPuma Biotechnology revenue growthCerus free cash flowPuma Biotechnology free cash flow
Cerus & Puma Biotechnology appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.